Zoono Files Legal Proceedings Against StayzonPosted by: Melbourne2006 | Posted on: December 4, 2018
Global biotech company, Zoono Group Limited (ASX: ZNO) (‘Zoono’ or ‘the Company’), advises that it has commenced legal proceedings against MCS Capital Partners Pty Limited and Stayzon Retail Ventures Pty Limited (together, ‘Stayzon’) for breach of the Deed of Settlement pursuant to which Zoono and Stayzon ended their supply agreement in March 2018.
Zoono believes Stayzon has engaged in, and continues to engage in, making false and misleading statements in the marketing and sale of Stayzon products. Proceedings have been filed in the Auckland High Court. Zoono will advise of the outcome of these proceedings in due course.
For further Information please contact:
+64 21 659977
Zoono is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono’s mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.
Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘zoono molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.
Zoono’s products have received numerous regulatory approvals and the company’s technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.
To learn more, please visit: www.zoono.com
The Capital Network
P: +61 419 815 386
MCS Capital Partners Pty Limited | Stayzon Retail Ventures Pty Limited | Zoono Group Limited | ZNO
Information contained on this page was released on the ASX on 3rd December 2018 and provided by independent content providers. Melbourne 2006 make no warranties or representations in connection therewith. If you have any questions or comments about this page please forward them via one of the methods detailed on the Contact Us page.